NephroGenex Inc (NRX)

0.04
0.00 6.94
OTC : Health Care
Prev Close 0.04
Open 0.04
Day Low/High 0.04 / 0.04
52 Wk Low/High 0.04 / 4.57
Volume 3.00K
Avg Volume 296.00K
Exchange OTC
Shares Outstanding 12.95M
Market Cap 1.81M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NephroGenex To Host Conference Call And Webcast On Fourth Quarter And Full Year 2015 Financial Results On Thursday, February 25, 2016

NephroGenex To Host Conference Call And Webcast On Fourth Quarter And Full Year 2015 Financial Results On Thursday, February 25, 2016

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report its fourth quarter and full year 2015 financial results on Wednesday, February 24...

NephroGenex To Present At The 18th Annual BIO CEO & Investor Conference

NephroGenex To Present At The 18th Annual BIO CEO & Investor Conference

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that CEO and President Pierre Legault will present a corporate overview of the...

NephroGenex Announces Independent DSMB Recommendation To Continue Phase 3 Study Of Oral Pyridorin In Diabetic Nephropathy Without Modification

NephroGenex Announces Independent DSMB Recommendation To Continue Phase 3 Study Of Oral Pyridorin In Diabetic Nephropathy Without Modification

NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's...

NephroGenex To Participate In Two Healthcare Conferences In January

NephroGenex To Participate In Two Healthcare Conferences In January

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that CEO and President Pierre Legault will present a corporate overview of the...

NephroGenex Announces Formation Of Scientific Advisory Board

NephroGenex Announces Formation Of Scientific Advisory Board

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of leading experts in nephrology to its newly formed Scientific...

NephroGenex (NRX) Stock Soars After FDA Approves Clinical Trials for Kidney Treatment

NephroGenex (NRX) Stock Soars After FDA Approves Clinical Trials for Kidney Treatment

NephroGenex (NRX) stock is rising on heavy trading volume on Monday after the FDA approved the start of clinical trials for the company's acute kidney injury treatment.

NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury

NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the U.

NephroGenex Reports Third Quarter 2015 Financial Results

NephroGenex Reports Third Quarter 2015 Financial Results

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the third quarter ended September 30,...

NephroGenex Announces Successful Results From Toxicity Study Of Intravenous Pyridorin

NephroGenex Announces Successful Results From Toxicity Study Of Intravenous Pyridorin

NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced successful results from a preclinical toxicity study of intravenous...

NephroGenex To Host Conference Call And Webcast On Third Quarter 2015 Financial Results On Thursday, November 12, 2015

NephroGenex To Host Conference Call And Webcast On Third Quarter 2015 Financial Results On Thursday, November 12, 2015

NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report financial results for the quarter ended September 30, 2015 on Wednesday, November 11,...

NephroGenex Announces $5.5 Million Private Placement

NephroGenex Announces $5.5 Million Private Placement

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced it has entered into a definitive agreement to sell securities to healthcare...

NephroGenex To Present At The 2015 Aegis Growth Conference

NephroGenex To Present At The 2015 Aegis Growth Conference

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault will present a corporate overview of...

NephroGenex To Participate In Two Healthcare Conferences In September

NephroGenex To Participate In Two Healthcare Conferences In September

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault and other members of management will...

NephroGenex Reports Second Quarter 2015 Financial Results

NephroGenex Reports Second Quarter 2015 Financial Results

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the second quarter ended June 30,...

NephroGenex To Host Conference Call And Webcast On Second Quarter 2015 Financial Results On Thursday, August 13, 2015

NephroGenex To Host Conference Call And Webcast On Second Quarter 2015 Financial Results On Thursday, August 13, 2015

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report financial results for the quarter ended June 30, 2015 on Wednesday, August 12, after...

NephroGenex Appoints Dr. Jaikrishna Patel As Chief Medical Officer

NephroGenex Appoints Dr. Jaikrishna Patel As Chief Medical Officer

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the appointment of Dr.

NephroGenex, Inc. Announces Closing Of Public Offering Of Common Stock And Warrants

NephroGenex, Inc. Announces Closing Of Public Offering Of Common Stock And Warrants

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the closing of its previously announced underwritten public offering of 1,500,000...

NephroGenex, Inc. Prices $7,500,000 Public Offering

NephroGenex, Inc. Prices $7,500,000 Public Offering

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the pricing of an underwritten public offering of 1,500,000 shares of its common...

5 Stocks Ready for Breakouts

5 Stocks Ready for Breakouts

These stocks are ready to break out and trade higher from current levels.

NephroGenex To Participate In Two Healthcare Conferences In June

NephroGenex To Participate In Two Healthcare Conferences In June

NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault will present a corporate overview of...

NephroGenex Reports First Quarter 2015 Financial Results

NephroGenex Reports First Quarter 2015 Financial Results

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and clinical program highlights for the first quarter ended March...

CORRECTING and REPLACING NephroGenex To Host Conference Call and Webcast on First Quarter 2015 Financial Results on Thursday, May 14, 2015

CORRECTING and REPLACING NephroGenex To Host Conference Call and Webcast on First Quarter 2015 Financial Results on Thursday, May 14, 2015

Headline of release should read: NephroGenex To Host Conference Call and Webcast on First Quarter 2015 Financial Results on Thursday, May 14, 2015 (instead of March 14, 2015) The corrected release reads: ...

NephroGenex Announces Proposed Offering Of Common Stock

NephroGenex Announces Proposed Offering Of Common Stock

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that it has commenced an underwritten public offering of shares of its common...

NephroGenex Announces Data On Acute Kidney Injury At National Kidney Foundation 2015 Spring Clinical Meetings

NephroGenex Announces Data On Acute Kidney Injury At National Kidney Foundation 2015 Spring Clinical Meetings

NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced positive results on preclinical studies that evaluate Pyridorin ® as a...

NephroGenex Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014

NephroGenex Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today reported financial results and business highlights for the fourth quarter and year ended...

NephroGenex To Host Conference Call On Fourth Quarter And Full Year 2014 Financial Results On Wednesday, March 25, 2015

NephroGenex To Host Conference Call On Fourth Quarter And Full Year 2014 Financial Results On Wednesday, March 25, 2015

NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, will report its fourth quarter and full year 2014 financial results on Tuesday, March 24, 2015...

3 Health Care Stocks Under $10 to Trade for Breakouts

3 Health Care Stocks Under $10 to Trade for Breakouts

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

NephroGenex To Present At The Cowen And Company 35th Annual Health Care Conference

NephroGenex To Present At The Cowen And Company 35th Annual Health Care Conference

NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault and President and Chief Scientific...